Education
About Us
Working with TipRanks
Follow Us
Avacta Group PLC (GB:AVCT)
LSE:AVCT
Earnings Data
Report Date
Sep 25, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Jun 06, 2025
|% Change Since: -1.90%
|Next Earnings Date:Sep 25, 2025
Earnings Call Sentiment|Neutral
Avacta has made significant progress in transforming into a focused oncology biopharmaceutical company and advancing its clinical programs. While there is excitement around the clinical data and strategic collaborations, financial losses and funding needs pose challenges. The company's long-term potential is promising, but market conditions and operational hurdles present ongoing concerns.Company Guidance
In the recent investor call, Avacta Group Plc provided detailed guidance on their fiscal year 2024 results and strategic direction. The company has repositioned itself as a pure-play oncology biopharmaceutical entity, having divested its diagnostics segment. Among key metrics, Avacta highlighted its cash position of $17.3 million as of April 2025, following a divestment, which extends its cash runway into the first quarter of 2026. R&D expenses were reported at $14.27 million, with administrative expenses increasing to $12.05 million due to executive changes and professional expenses. The overall loss from continuing operations was $28.98 million. Avacta's FAP-Dox program, a key clinical focus, has advanced with the completion of Phase Ia and the opening of Phase Ib expansion cohorts, targeting salivary gland and triple-negative breast cancers. Initial data from these cohorts is expected in late 2025 and early 2026, respectively. Additionally, the FAP-Exatecan program is in IND-enabling status, with clinical trials anticipated to start in early 2026. The company also announced strategic collaborations and emphasized their intellectual property advancements, including a sustained release mechanism filed in September 2024. Avacta is exploring a potential dual listing on NASDAQ to enhance its capital market strategy and is actively seeking partnerships to accelerate the development of its pre|CISION platform assets.Transformation to Oncology Focus
Avacta has successfully transitioned into a pure-play oncology biopharmaceutical company, focusing on their proprietary pre|CISION peptide drug conjugate platform.
Clinical Progress in FAP-Dox
The FAP-Dox program completed Phase Ia, showing elimination of cardiac toxicity, proof-of-concept, and a disease control rate of over 90% in salivary gland cancer.
Strategic Collaboration with Tempus
Avacta entered into a strategic collaboration with Tempus, leveraging AI to drive smarter clinical trials and refine indication selection for the FAP exatecan program.
Financial Position and Cash Runway
Avacta reported a cash position of $17.3 million as of April 2025, following the divestment of the Diagnostics business, extending the cash runway into the first quarter of 2026.
Intellectual Property and Sustained Release Mechanism
New intellectual property was filed, including a sustained release mechanism, providing a reset for the company's IP position and opening new therapeutic opportunities.
GB:AVCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:AVCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jun 06, 2025 | 34.25p | 32.50p | -5.11% |
Sep 30, 2024 | 51.50p | 49.00p | -4.85% |
Apr 30, 2024 | 48.30p | 45.75p | -5.28% |
Sep 28, 2023 | 122.50p | 122.50p | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Avacta Group PLC (GB:AVCT) report earnings?
Avacta Group PLC (GB:AVCT) is schdueled to report earning on Sep 25, 2025, TBA Not Confirmed.
What is Avacta Group PLC (GB:AVCT) earnings time?
Avacta Group PLC (GB:AVCT) earnings time is at Sep 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Avacta Group PLC stock?
The P/E ratio of Avacta Group plc is N/A.
What is GB:AVCT EPS forecast?
Currently, no data Available